AbbVie’s recent $10.9 billion acquisition of the cancer drug maker Allergan has sent ripples through the stock market, particularly affecting the Nasdaq-100. This significant deal aims to bolster AbbVie’s portfolio, enhancing its position in oncology and addressing the looming patent expirations of its top-selling drug, Humira. Investors reacted with enthusiasm, driving shares of both companies higher in pre-market trading.
Simultaneously, Nasdaq-100’s annual rebalance introduced additional volatility. This routine adjustment affects stock prices as companies are added or removed based on market capitalization, creating fluctuations in volatile sectors. The combination of AbbVie’s acquisition announcement and the Nasdaq-100 rebalance has led to heightened trading activity and uncertainty, as investors reassess their strategies in response to these developments. Overall, the dual impact has not only affected individual stocks but has also contributed to broader market dynamics, underscoring how corporate actions and structural changes in indices can induce overnight volatility.
For more details and the full reference, visit the source link below:
Read the complete article here: https://www.stl.news/global-market-update/